1Berke G.Unlocking the secrets of CTL and NK cells[J].Immund Today,1995,16(7):343.
2Schreter M,Lowin B,Borner C,et al.regulation of Fas(APO-1/CD95)and perforinmediated lyric pathways of primary cytotoxic T Lymphocytes by the protooncogene bel-2[J].Eurp J Immunol,1995,25:3509.
3Davis ID,Chen W,Jackson H,et al.Recombinant NY-ESO-1 protein with iscomatrix adjuvant induces broad integrated antibody and CD4(+)and CD8(+)T cell responses in humans[J].Proc NatlAcad Sci USA,2004,101(29):10697.
4Van Baren N,Bonnet MC,Dreno B,et al.Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells[J].J Clin Oncol,2005,23(35):9008.
5Joseph N,Blattman,Philip D.Cancer Immunotherapy:A Treatment for the Masses[J].Science,2004,305:200.
6Kalinski P,Mailliard RB,Giermasz A,et al.Natural killerdendritic cell cross-talk in cancer immunotherapy[J].Expert Opin Biol Ther,2005,5(10):1303.
7Kuroki M,Hachimine K,Huang J,et al.Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity[J].Anticancer Res,2005,25(6A):3725.
8Osada T,Clay T,Hobeika A,et al.NK cell activation by dendritic cell vaccine:a mechanism of action for clinical activity[J].Cancer Immunol Immunother,2006,55(9):1122.
9Kuo-Ching S,Geoff AP,Mark DW,et al.Dendritic cells:activation and maturation-application for cancer immunotherapy[J].Current Medicinal Chemistry,2005,12(15):1783.
10Jacalyn R,Donald K,David A.Dendritce cell vaccines for cancer immunotherapy[J].Expert Opin Biol Ther,2005,5(5):703.
